---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-002289"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2022-02-03T23:59:59+00:00"
generated_at: "2026-06-27T12:01:02.251745+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs Q3 revenue up 60% to $54.7M; GAAP operating loss $2.5M on Agena acquisition costs

## Summary
- Q3 revenue $54.7M (+60% YoY); organic revenue growth 12%.
- GAAP operating loss $2.5M; net loss $0.39/diluted share.
- Non-GAAP adjusted op. income $7.1M; excl. unusual items $13.8M (+73%).
- Biopharma division organic growth 46%; Calibration Solutions revenue fell 6%.
- Acquired Agena Bioscience in Oct 2021; cash reserves fell from $264M to $52M.

## SEC filing metadata
- accession: 0001437749-22-002289
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2022-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774922002289/0001437749-22-002289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774922002289/mlab20220201_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-002289
- JSON: https://secwatch.observer/filing/0001437749-22-002289.json
- Plain text: https://secwatch.observer/filing/0001437749-22-002289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.